Drug intelligence / Profile preview

SR-1401

Development stage: Preclinical
Lead developer: Sigmapharm Laboratories
Modality: Small Molecules

Overview

SR-1401 is a generic small-molecule drug candidate developed by SigmaPharm Laboratories. It is a sustained-release (SR) formulation currently in the company's pipeline, with an Abbreviated New Drug Application (ANDA) or similar regulatory filing indicated. SigmaPharm specializes in developing complex generic products using proprietary drug delivery systems, including extended-release, sustained-release, and sublingual technologies. The specific active pharmaceutical ingredient (API) and therapeutic indication for SR-1401 have not been publicly disclosed, as is common for generic products in the pre-approval stage. The formulation is designed to provide controlled release of the medication, potentially improving patient compliance or reducing side effects compared to immediate-release versions.

Other names: SR-1401-SigmaPharm-generic small-molecule formulationSR1401-SigmaPharm-generic small-molecule formulationSR 1401-SigmaPharm-generic small-molecule formulation

Beyond the preview

Go deeper on SR-1401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SR-1401.

Explore the full profile